Altria purchases a potentially-majority stake in Cronos for C$2.4 billion.

This is a great deal for Cronos shareholders, who will not benefit from the expertise of Altria and management will have a deep war-chest for potential expansion and acquisitions.

This is a risky deal for Altria shareholders who are paying a high price for a mid-sized Canadian cannabis company.

This is a loss for Aphria, whose shareholders hoped they could receive an Altria investment.

READ FULL ARTICLE HERE